Association between cyclin D1 G870A polymorphism and cervical cancer risk: a cumulative meta-analysis involving 2,864 patients and 3,898 controls

Diagnostic Pathology

Yu-Ming Niu¹  Chong Guo³  Rong Zheng³  Yuan-Yuan Hu² 

[1] Clinical and Evidence-Based Medicine Center, Taihe Hospital, Hubei University of Medicine, Shiyan, P. R. China;Department of Stomatology, Taihe Hospital, Hubei University of Medicine, 32 South Renmin Road, Shiyan 442000, China;Department of gynaecology and obstetrics, Taihe Hospital, Hubei University of Medicine, 32 South Renmin Road, Shiyan 442000, China

关键词: Meta-analysis;    Cervical cancer;    Polymorphism;    CCND1;   

Others  :  1149905
DOI  :  10.1186/s13000-014-0168-x

 received in 2014-06-21, accepted in 2014-08-16,  发布年份 2014

【 摘 要 】

Background

Association between Cyclin D1 (CCND1) polymorphism and cervical cancer risk are conflicting with published articles. We performed a meta-analysis to investigate the association between CCND1 G870A polymorphism and cervical cancer risk.

Methods

PubMed, Embase and CNKI data were researched to conduct a meta-analysis on the associations between CCND1 G870A polymorphism and cervical cancer risk. Ten published case¿control studies including 2,864 patients with cervical cancer and 3,898 controls were collected in this meta-analysis. Odds ratio (OR) with 95% confidence interval (CI) were applied to assess the relationship; meta-regression, sensitivity analysis and cumulative analysis were also conducted to guarantee the strength of results.

Results

Overall, no significant association between CCND1 G870A polymorphism and cervical cancer risk were found in allele contrast (A vs. G: OR?=?1.02, 95% CI?=?0.88-1.19, P?=?0.76 I²?=?74.5%), codominant model (GA vs. GG: OR?=?0.98, 95% CI?=?0.77-1.26, P?=?0.90 I²?=?69.1%; AA vs GG: OR?=?1.03, 95% CI?=?0.75-1.41, P?=?0.85 I²?=?75.9%), dominant model (GA + AA vs. GG: OR?=?1.00, 95% CI?=?0.78-1.28, P?=?0.99 I²?=?72.3%) and recessive model (AA vs GG + GA: OR?=?1.06, 95% CI?=?0.85-1.23, P?=?0.62, I²?=?70.1%). Similarly, in the stratified analysis by ethnicity, study design and genotyping type, no significant association detected in all genetic models either.

Conclusions

Our meta-analysis indicated that CCND1 G870A might be not the crucial risk factor for the development of cervical cancer.

Virtual Slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_168 webcite

【 授权许可】

   
2014 Hu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [2]Garcia-Espinosa B, Nieto-Bona MP, Rueda S, Silva-Sanchez LF, Piernas-Morales MC, Carro-Campos P, Cortes-Lambea L, Moro-Rodriguez E: Genotype distribution of cervical human papillomavirus DNA in women with cervical lesions in bioko, equatorial guinea. Diagn Pathol 2009, 4:31. BioMed Central Full Text
• [3]Tang SY, Li L, Li YL, Liu AY, Yu MJ, Wan YP: Distribution and location of daxx in cervical epithelial cells with high risk human papillomavirus positive. Diagn Pathol 2014, 9:1. BioMed Central Full Text
• [4]Galderisi U, Jori FP, Giordano A: Cell cycle regulation and neural differentiation. Oncogene 2003, 22:5208-5219.
• [5]Sherr CJ: Cancer cell cycles. Science 1996, 274:1672-1677.
• [6]Zhang B, Liu W, Li L, Lu J, Liu M, Sun Y, Jin D: Kai1/cd82 and cyclin d1 as biomarkers of invasion, metastasis and prognosis of laryngeal squamous cell carcinoma. Int J Clinical Exp Pathol 2013, 6:1060-1067.
• [7]Myong NH: Cyclin d1 overexpression, p16 loss, and prb inactivation play a key role in pulmonary carcinogenesis and have a prognostic implication for the long-term survival in non-small cell lung carcinoma patients. Cancer Res Treat 2008, 40:45-52.
• [8]Abramson VG, Troxel AB, Feldman M, Mies C, Wang Y, Sherman L, McNally S, Diehl A, Demichele A: Cyclin d1b in human breast carcinoma and coexpression with cyclin d1a is associated with poor outcome. Anticancer Res 2010, 30:1279-1285.
• [9]Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J: Alternate splicing produces a novel cyclin d1 transcript. Oncogene 1995, 11:1005-1011.
• [10]Catarino R, Matos A, Pinto D, Pereira D, Craveiro R, Vasconcelos A, Lopes C, Medeiros R: Increased risk of cervical cancer associated with cyclin d1 gene a870g polymorphism. Cancer Genet Cytogenet 2005, 160:49-54.
• [11]Wu Y, Fu H, Zhang H, Huang H, Chen M, Zhang L, Yang H, Qin D: Cyclin d1 (ccnd1) g870a polymorphisms and cervical cancer susceptibility: a meta-analysis based on ten case¿control studies. Tumour Biol 2014, 35:6913-6918.
• [12]Jeon YT, Kim JW, Song JH, Park NH, Song YS, Kang SB, Lee HP: Cyclin d1 g870a polymorphism and squamous cell carcinoma of the uterine cervix in korean women. Cancer Lett 2005, 223:259-263.
• [13]Catarino R, Pereira D, Breda E, Coelho A, Matos A, Lopes C, Medeiros R: Oncogenic virus-associated neoplasia: a role for cyclin d1 genotypes influencing the age of onset of disease? Biochem Biophys Res Commun 2008, 370:118-122.
• [14]Satinder K, Chander SR, Pushpinder K, Indu G, Veena J: Cyclin d1 (g870a) polymorphism and risk of cervix cancer: a case control study in north indian population. Mol Cell Biochem 2008, 315:151-157.
• [15]Thakur N, Hussain S, Kohaar I, Tabassum R, Nasare V, Tiwari P, Batra S, Bhambhani S, Das BC, Basir SF, Bharadwaj D, Bharadwaj M: Genetic variant of ccnd1: association with hpv-mediated cervical cancer in indian population. Biomarkers 2009, 14:219-225.
• [16]Castro FA, Haimila K, Sareneva I, Schmitt M, Lorenzo J, Kunkel N, Kumar R, Forsti A, Kjellberg L, Hallmans G, Lehtinen M, Hemminki K, Pawlita M: Association of hla-drb1, interleukin-6 and cyclin d1 polymorphisms with cervical cancer in the swedish population¿a candidate gene approach. Int J Cancer 2009, 125:1851-1858.
• [17]Ni J, Wang M, Fu S, Zhou D, Zhang Z, Han S: Ccnd1 g870a polymorphism and cervical cancer risk: a case¿control study and meta-analysis. J Cancer Res Clin Oncol 2011, 137:489-494.
• [18]Warchol T, Kruszyna L, Lianeri M, Roszak A, Jagodzinski PP: Distribution of ccnd1 a870g polymorphism in patients with advanced uterine cervical carcinoma. Pathol Oncol Res 2011, 17:133-137.
• [19]Wang N, Qian X, Wang S, Gao H, Wang L, Huo Y, Zhang S: Ccnd1 rs9344 polymorphisms are associated with the genetic susceptibility to cervical cancer in chinese population. Mol Carcinog 2012, 51:196-205.
• [20]Djansugurova LB, Perfilyeva AV, Zhunusova GS, Djantaeva KB, Iksan OA, Khussainova EM: The determination of genetic markers of age-related cancer pathologies in populations from kazakhstan. Front Genet 2013, 4:70.
• [21]Comstock CE, Augello MA, Benito RP, Karch J, Tran TH, Utama FE, Tindall EA, Wang Y, Burd CJ, Groh EM, Hoang HN, Giles GG, Severi G, Hayes VM, Henderson BE, Le Marchand L, Kolonel LN, Haiman CA, Baffa R, Gomella LG, Knudsen ES, Rui H, Henshall SM, Sutherland RL, Knudsen KE: Cyclin d1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res 2009, 15:5338-5349.
• [22]Yaylim-Eraltan I, Arikan S, Yildiz Y, Cacina C, Ergen HA, Tuna G, Gormus U, Zeybek U, Isbir T: The influence of cyclin d1 a870g polymorphism on colorectal cancer risk and prognosis in a turkish population. Anticancer Res 2010, 30:2875-2880.
• [23]Sergentanis TN, Economopoulos KP: Cyclin d1 g870a polymorphism and breast cancer risk: a meta-analysis comprising 9,911 cases and 11,171 controls. Mol Biol Rep 2011, 38:4955-4963.
• [24]Tsai MH, Tsai CW, Tsou YA, Hua CH, Hsu CF, Bau DT: Significant association of cyclin d1 single nucleotide polymorphisms with oral cancer in Taiwan. Anticancer Res 2011, 31:227-231.
• [25]Akkiz H, Bayram S, Bekar A, Akgollu E, Ozdil B: Cyclin d1 g870a polymorphism is associated with an increased risk of hepatocellular carcinoma in the turkish population: case¿control study. Cancer Epidemiol 2010, 34:298-302.
• [26]Shen SN, Wang LF, Jia YF, Hao YQ, Zhang L, Wang H: Upregulation of microrna-224 is associated with aggressive progression and poor prognosis in human cervical cancer. Diagn Pathol 2013, 8:69. BioMed Central Full Text
• [27]Habbous S, Pang V, Eng L, Xu W, Kurtz G, Liu FF, Mackay H, Amir E, Liu G: P53 arg72pro polymorphism, hpv status and initiation, progression, and development of cervical cancer: a systematic review and meta-analysis. Clin Cancer Res 2012, 18:6407-6415.